Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Feb. 19, 2020 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
Data from initial patients who have completed the ongoing open label Edge trial show that IGF-1 levels were maintained after 13 weeks of treatment when patients were switched to once daily oral paltusotine from commercially available depot injections of the peptide somatostatin receptor ligands, octreotide or lanreotide. Results as of a February 23, 2020 data cutoff showed that acromegaly patients switching from injectable depot therapy to once daily oral paltusotine (formerly CRN00808) maintained IGF-1 levels previously achieved with commercially available depot injections of somatostatin receptor ligands (SRLs).
How do we determine whether Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
SAN DIEGO, Nov. 12, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has closed its previously announced underwritten public offering of 8,222,500 shares of its common stock, including 1,072,500 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $14.00 per share. Crinetics intends to use the net proceeds from the offering to fund the development of paltusotine and its other research and development programs, and for working capital and general corporate purposes. The securities described above were offered by Crinetics pursuant to a shelf registration statement previously filed and declared effective by the Securities and Exchange Commission (SEC).
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 7,150,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares to be sold in the offering are being sold by Crinetics. In addition, Crinetics has granted the underwriters a 30-day option to purchase up to an additional 1,072,500 shares of common stock.
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Crinetics.
Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Adriana Cabré, MBA, as Vice President of Human Resources. “We are pleased to welcome Adriana to the executive team to lead our Human Resource function,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics.
SAN DIEGO, Jan. 08, 2020 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
While not a mind-blowing move, it is good to see that the Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) share price...
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) * Forty Seven Inc (NASDAQ: FTSV) * Masimo Corporation (NASDAQ: MASI) * Seattle Genetics, Inc. (NASDAQ: SGEN) * Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)Down In The Dumps (Biotech stocks that hit 52-week lows April 6) * BIOLASE Inc (NASDAQ: BIOL) * China SXT Pharmaceuticals Inc (NASDAQ: SXTC) * ENDRA Life Sciences Inc (NASDAQ: NDRA) * Global Cord Blood Corp (NYSE: CO) * ImmuCell Corporation (NASDAQ: ICCC) * IMMURON LTD/S ADR (NASDAQ: IMRN) * Menlo Therapeutics Inc (NASDAQ: MNLO) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) * Merus NV (NASDAQ: MRUS) * Millendo Therapeutics Inc (NASDAQ: MLND) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) * Obalon Therapeutics Inc (NASDAQ: OBLN) * Quest Diagnostics Inc (NYSE: DGX) (said it has performed 550,000 COVID-19 tests) * Second Sight Medical Products Inc (NASDAQ: EYES)Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced they have finalized the planned restructuring related to cholesterol drug Praluent. Effective April 1, Sanofi will have the sole responsibility for Praluent outside the U.S., while Regeneron assumes the sole responsibility in the U.S. The companies entered into an agreement to support manufacturing needs in the near term.The intention to restructure the antibody collaboration was announced in December 2019. Crinetics Reports Positive Results In Midstage Study Of Paltusotine Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) announced positive interim results from the ongoing ACROBAT Edge Phase 2 trial that is evaluating the safety and efficacy of paltusotine in patients with acromegaly who have not achieved normal IGF-1 levels despite stable therapy with a somatostatin receptor ligands, or SRL, or with a SRL in combination with a dopamine agonist.The company said enrollment in the ACROBAT Edge study is complete, with topline data expected in the fourth quarter of 2020.The company also said it plans to advance paltusotine for acromegaly into Phase 3 trials in the first half of 2021 and into Phase 2 trials for patients with neuroendocrine tumors who suffer from carcinoid syndrome.See also: The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations AIM ImmunoTech To Test Ampligen Delivery Using Vaping Device For Coronavirus In China AIM ImmunoTech Inc (NYSE: AIM) said it has entered into a material transfer and research agreement with vaping device maker Shenzhen Smoore Technology to research in China the efficacy of Smoore's inhalation delivery device using Ampligen.Ampligen is AIM's lead drug which has been approved for myalgic encephalomyelitis and chronic fatigue syndrome in Argentina.AIM said it believes Ampligen has potential as a prophylactic/early-onset therapeutic against COVID-19 caused by the new coronavirus, as it has yielded 100% protective efficacy against SARS-CoV-1 viral infection in duplicate experiments using a mouse model in U.S.View more earnings on IBBThe stock was down 0.35% at $2.84 in Tuesday's premarket session. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Natus Lowers Q1 Revenue Guidance Due To COVID-19 Impact Natus Medical Inc (NASDAQ: NTUS) announced preliminary first-quarter revenue of $109 million to $110 million, lower than its previous guidance of $113 million to $117 million. The company blamed the shortfall relative to the guidance to the COVID-19 pandemic. The company also withdrew its 2020 guidance.In premarket trading Tuesday, the stock was slipping 2.17% to $22.25.Announcements On COVID-Related Impacts Alcon AG (NYSE: ALC) said it is withdrawing its 2020 guidance. The company also said it has withdrawn the dividend proposal to be discussed at its May 6 annual general meeting. The company plans to delay dividend initiation until 2021.The stock was down 1.41% at $51.58 in Tuesday's premarket session. Morphosys Ag (NASDAQ: MOR) said it is temporarily pausing enrollment and screening of patients in the M-PLACE study with MOR202. The company said it plans to continue enrollment of patients in studies with the potential for significant benefit in life-threatening conditions.As of now, the company said it is maintaining its previously communicated 2020 guidance with respect to corporate milestones.Zimmer Biomet Holdings Inc (NYSE: ZBH) lowered its first-quarter revenue growth guidance to negative 9.5%-10.5%, citing a significant and sudden decline in elective procedure volume due to the COVID-19 pandemic. Analysts, on average, currently expect a 2.7% year-over-year revenue decline. The company also withdrew its full-year guidance.Penumbra Inc (NYSE: PEN) pre-announced first-quarter revenue of $137 million to $137.3 million, below the consensus estimate of $138.08 million. The company also withdrew its guidance.On The Radar Earnings * AngioDynamics, Inc. (NASDAQ: ANGO) (after the close)Related Link: Co-Diagnostics COVID-19 Test Gets FDA Emergency Use Authorization See more from Benzinga * The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO * The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
SAN DIEGO, March 09, 2020 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -11.11% and 51.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update. “So far, 2020 has proven to be a transformational time for Crinetics, highlighted by the positive interim Phase 2 results for paltusotine, our lead product candidate for the treatment of acromegaly,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics.
Crinetics Pharmaceuticals (CRNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
SAN DIEGO, Nov. 26, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
Crinetics Pharmaceuticals, Inc. (CRNX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.